Interplay of choline metabolites and genes in patient-derived breast cancer xenografts

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Grinde, Maria T ^a,b   Skrbo, Nirma ^c,d   Moestue, Siver A ^a,b   Rødland, Einar A ^e   Borgan, Eldrid ^a,c,d   Kristian, Alexandr ^c,d   Sitter, Beathe ^a   Bathen, Tone F ^a,b   Børresen Dale, Anne Lise ^c,d   Mælandsmo, Gunhild M ^c,f   Engebraaten, Olav ^d,g   Sørlie, Therese ^c   Marangoni, Elisabetta ^h   Gribbestad, Ingrid S ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f UNIVERSITY OF TROMSØ   (Norway)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE DERIVATIVE; CHOLINE KINASE ALPHA; ENZYME; GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE DOMAIN CONTAINING 5; GLYCEROPHOSPHORYLCHOLINE; PHOSPHORYLCHOLINE; UNCLASSIFIED DRUG; CHKA PROTEIN, HUMAN; CHOLINE; CHOLINE KINASE; GLYCEROPHOSPHODIESTER PHOSPHODIESTERASE; PHOSPHODIESTERASE; TRANSCRIPTOME;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST TUMOR; CHOLINE GENE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION; HIGH RESOLUTION MAGIC ANGLE SPINNING MR SPECTROSCOPY; HUMAN; HUMAN TISSUE; METABOLITE; METABOLOMICS; MICROARRAY ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TRANSCRIPTOMICS; TUMOR GENE; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; TISSUE MICROARRAY; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CHOLINE; CHOLINE KINASE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCERYLPHOSPHORYLCHOLINE; HUMANS; METABOLOMICS; MICE; NEOPLASM TRANSPLANTATION; PHOSPHORIC DIESTER HYDROLASES; PHOSPHORYLCHOLINE; TISSUE ARRAY ANALYSIS; TRANSCRIPTOME; TRANSPLANTATION, HETEROLOGOUS;

EID: 84896709072     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3597     Document Type: Article

References (63)

1. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 2007, 7:545-553.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, de RM V, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
4. Li SX, Sjolund A, Harris L, Sweasy JB. DNA repair and personalized breast cancer therapy. Environ Mol Mutagen 2010, 51:897-908.
5. Fiebig HH, Burger AM. Human tumor xenografts and explants. Tumor Models in Cancer Research 2002, 167-193. Totowa: Humana Press Inc, Teicher BA.
6. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Diéras V, Poupon MF. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007, 13:3989-3998.
7. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 2012, 14:R11.
8. Bergamaschi A, Hjortland GO, Triulzi T, Sorlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 2009, 3:469-482.
9. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011, 17:1514-1520.
10. Kelland LR. "Of mice and men": values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004, 40:827-836.
11. Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 2010, 12:473-480.
12. Sardanelli F, Fausto A, Di Leo G, de Nijs R, Vorbuchner M, Podo F. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. AJR Am J Roentgenol 2009, 192:1608-1617.
13. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001, 84:1016-1022.
14. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999, 59:80-84.
15. Singer S, Souza K, Thilly WG. Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: a 31P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study. Cancer Res 1995, 55:5140-5145.
16. Eliyahu G, Maril N, Margalit RH. Choline Metabolism in breast cancer; the influence of the microenvironmental conditions: [abstract]. Proc Intl Soc Mag Reson Med 2007, 2007:15.
17. Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjøsne HE, Dahl S, Gribbestad IS, Bathen TF. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res 2010, 9:972-979.
18. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 2006, 19:30-40.
19. Jensen LR, Huuse EM, Bathen TF, Goa PE, Bofin AM, Pedersen TB, Lundgren S, Gribbestad IS. Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo1H MRS. NMR Biomed 2010, 23:56-65.
20. Glunde K, Jie C, Bhujwalla ZM. Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia 2006, 8:758-771.
21. Cao MD, Sitter B, Bathen TF, Bofin A, Lønning PE, Lundgren S, Gribbestad IS. Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR Biomed 2011, 25:269-278.
22. Gallego-Ortega D, Sarmentero J, Bañez-Coronel M, Martín-Cantalejo Y, Lacal JC, Ramírez De Molina A. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res 2005, 65:5647-5653.
23. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer 2011, 11:835-848.
24. Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader C, de Plater L, Elbaz C, Karboul N, Fontaine J, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D. Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. Breast Cancer Res Treat 2012, 133:595-606.
25. Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Denoux Y, Fiche M, Jacquemier J, Mathieu MC, Penault-Llorca F, Rigaud C, Roger P, Treilleux I, Vilain MO, Mathoulin-Pélissier S, Le Doussal V. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS Study. Histopathology 2003, 42:337-347.
26. Navon R, Rødland E, Enerly E, Steinfeld I, Kleivi K, Leivonen S, Aure M, Russnes H, Rønneberg JH, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One 2011, 22:e16915.
27. Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjærde OC, Strømberg M, Wiedswang G, Kvalheim G, Kåresen R, Nesland JM, Børresen-Dale AL, Sørlie T. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol 2007, 1:160-171.
28. Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T, Rees CA, Cherry JM, Botstein D, Brown PO, Alizadeh AA. SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res 2003, 31:219-223.
29. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423.
30. Wider G, Dreier L. Measuring protein concentrations by NMR spectroscopy. J Am Chem Soc 2006, 128:2571-2576.
31. Eilers PH. Parametric time warping. Anal Chem 2003, 76:404-411.
32. Savorani F, Tomasi G, Engelsen SB. icoshift: a versatile tool for the rapid alignment of 1D NMR spectra. J Magn Reson 2010, 202:190-202.
33. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 2000, 28:27-30.
34. Michel V, Yuan ZM, Ramsubir S, Bakovic M. Choline transport for phospholipid synthesis. Exp Biol Med 2006, 231:490-504.
35. Gallazzini M, Ferraris JD, Burg MB. GDPD5 is a glycerophosphocholine phosphodiesterase that osmotically regulates the osmoprotective organic osmolyte GPC. Proc Natl Acad Sci USA 2008, 105:11026-11031.
36. Rosner B. Percentage points for a generalized ESD many-outlier procedure. Technometrics 1983, 25:165-172.
37. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9:R65.
38. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004, 40:2667-2675.
39. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100:10393-10398.
40. Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, Borresen-Dale AL, Engebraaten O, Maelandsmo GM, Gribbestad IS. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 2010, 10:433.
41. Galons JP, Job C, Gillies RJ. Increase of GPC levels in cultured mammalian cells during acidosis. A 31P MR spectroscopy study using a continuous bioreactor system. Magn Reson Med 1995, 33:422-426.
42. Mori N, Glunde K, Takagi T, Bhujwalla ZM. The tumor microenvironment alters choline phospholipid metabolism detected by comparing cancer cells with tumors: [abstract]. Proc Intl Soc Mag Reson Med 2008, 2008:16.
43. Contractor K, Kenny L, Stebbing J, Challapalli A, Al-Nahhas A, Palmieri C, Shousha S, Lewis J, Hogben K, De Nguyen Q, Coombes RC, Aboagye EO. Biological basis of [11C] choline-positron emission tomography in patients with breast cancer: comparison with [11 F] fluorothymidine positron emission tomography. Nucl Med Commun 2011, 32:997-1004.
44. Ebenhan T, Honer M, Ametamey SM, Schubiger PA, Becquet M, Ferretti S, Cannet C, Rausch M, McSheehy PJ. Comparison of [18 F]-tracers in various experimental tumor models by PET imaging and identification of an early response biomarker for the novel microtubule stabilizer patupilone. Mol Imaging Biol 2009, 11:308-321.
45. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer 2007, 120:1721-1730.
46. Kouji H, Inazu M, Yamada T, Tajima H, Aoki T, Matsumiya T. Molecular and functional characterization of choline transporter in human colon carcinoma HT-29 cells. Arch Biochem Biophys 2009, 483:90-98.
47. Ramírez de Molina A, Gutiérrez R, Ramos MA, Silva JM, Silva J, Bonilla F, Sánchez JJ, Lacal JC. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002, 21:4317-4322.
48. Moestue SA, Giskeødegård GF, Cao MD, Bathen TF, Gribbestad IS. Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer. Proc Natl Acad Sci USA 2012, 109:E2506.
49. Delikatny EJ, Chawla S, Leung DJ, Poptani H. MR-visible lipids and the tumor microenvironment. NMR Biomed 2011, 24:592-611.
50. Milkevitch M, Beardsley NJ, Delikatny EJ. Phenylbutyrate induces apoptosis and lipid accumulations via a peroxisome proliferator-activated receptor gamma-dependent pathway. NMR Biomed 2010, 23:473-479.
51. Milkevitch M, Shim H, Pilatus U, Pickup S, Wehrle JP, Samid D, Poptani H, Glickson JD, Delikatny EJ. Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. Biochim Biophys Acta 2005, 1734:1-12.
52. Morse DL, Raghunand N, Sadarangani P, Murthi S, Job C, Day S, Howison C, Gillies RJ. Response of choline metabolites to docetaxel therapy is quantified in vivo by localized 31P MRS of human breast cancer xenografts and in vitro by high-resolution 31P NMR spectroscopy of cell extracts. Magn Reson Imaging 2007, 58:270-280.
53. Cao MD, Döpkens M, Krishnamachary B, Vesuna F, Gadiya MM, Lønning PE, Bhujwalla ZM, Gribbestad IS, Glunde K. Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR Biomed 2012, 25:1033-1042.
54. Guthridge CJ, Stampfer MR, Clark MA, Steiner MR. Phospholipases A2 in ras-transformed and immortalized human mammary epithelial cells. Cancer Lett 1994, 86:11-21.
55. Morse DL, Carroll D, Day S, Gray H, Sadarangani P, Murthi S, Job C, Baggett B, Raghunand N, Gillies RJ. Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway. NMR Biomed 2009, 22:114-127.
56. Noh DY, Ahn SJ, Lee RA, Park IA, Kim JH, Suh PG, Ryu SH, Lee KH, Han JS. Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett 2000, 161:207-214.
57. Rebecchi MJ, Raghubir A, Scarlata S, Hartenstine MJ, Brown T, Stallings JD. Expression and function of phospholipase C in breast carcinoma. Adv Enzyme Regul 2009, 49:59-73.
58. Farooqui AA, Horrocks LA. Signaling and interplay mediated by phospholipases A2, C, and D in LA-N-1 cell nuclei. Reprod Nutr Dev 2005, 45:613-631.
59. Macara IG. Elevated phosphocholine concentration in ras-transformed NIH 3 T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown. Mol Cell Biol 1989, 9:325-328.
60. Ratnam S, Kent C. Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. Arch Biochem Biophys 1995, 323:313-322.
61. Mori N, Glunde K, Takagi T, Raman V, Bhujwalla ZM. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res 2007, 67:11284-11290.
62. Dawson SJ, Rueda OM, Aparicio S, Caldas C. A new genome-driven integrated classification of breast cancer and its implications. EMBO J 2013, 32:617-628.
63. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, et al. METABRIC Group The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. METABRIC Group.